TradingHolo

The whole market. One view. Market data from our own platform. Not investment advice. Prices in listing currency with AED alongside; market cap in USD. Live = streaming now; Delayed 15 min where the exchange requires it; At close = last official close.

News Calendar Economy IPOs ETFs Account

⌂Home ◈Markets ▦Screener 📈Tools ◎Portfolio

Skip to content

DFM General5,851.39−0.27%FTSE ADX9,783.24−0.26%TASI10,123.62−0.65%QE Index8,632.66−0.01%S&P 5007,690.73+0.41%Nasdaq 10029,529.34+1.17%Nifty 5022,888.95−1.11%Sensex73,852.90−1.17%KSE-100165,966.09−0.27%DFM:EMIRATESNBDAED 31.50−0.25%ADX:IHCAED 352.00−0.17%SAU:2222SAR 25.80+0.00%DSMD:QNBKQAR 15.66+2.29%NAS:NVDA$217.09+1.38%NYSE:TSM$420.22+1.84%NSE:RELIANCE₹1,202.00−0.76%KAR:OGDCRs 299.47+0.12%Gold$4,136.92−0.09%Brent$109.07−0.13%BTC$81,806.54−0.25%ETH$2,403.53−0.16%DFM General5,851.39−0.27%FTSE ADX9,783.24−0.26%TASI10,123.62−0.65%QE Index8,632.66−0.01%S&P 5007,690.73+0.41%Nasdaq 10029,529.34+1.17%Nifty 5022,888.95−1.11%Sensex73,852.90−1.17%KSE-100165,966.09−0.27%DFM:EMIRATESNBDAED 31.50−0.25%ADX:IHCAED 352.00−0.17%SAU:2222SAR 25.80+0.00%DSMD:QNBKQAR 15.66+2.29%NAS:NVDA$217.09+1.38%NYSE:TSM$420.22+1.84%NSE:RELIANCE₹1,202.00−0.76%KAR:OGDCRs 299.47+0.12%Gold$4,136.92−0.09%Brent$109.07−0.13%BTC$81,806.54−0.25%ETH$2,403.53−0.16%

Stock markets

🇦🇪UAEDFM · ADX · DFM GeneralClosed 🇸🇦Saudi ArabiaTadawul · TASIClosed 🇶🇦QatarQSE · QE GeneralClosed 🇺🇸United StatesNasdaq · NYSE · S&P 500Closed 🇮🇳IndiaNSE · BSE · Nifty 50Closed 🇵🇰PakistanPSX · KSE-100Closed

Other assets

₿CryptoRanked by volume · 24/7 🥇Gold, FX & economyDubai gold, AED crosses, rates ◫ETFsIndex, sector and gold funds

Explore

▦Market mapEvery market as a heatmap 📅Calendar & IPOsEarnings, dividends, listings, releases ⌁Options flow · Ownership · PoliticsUS filings and tapes

⚲Stock screenerAll six markets, one row per company ★Ready-made screensStarting points with a point of view 📁My saved screensSaved rules with alerts on new matches ⇄CompareUp to five, side by side

📈ChartingDrawings, indicators, replay ▶Strategy MakerWrite a rule, test it on history ⇄CompareSide by side 🔔AlertsPrice, earnings, screens, strategies

⌕

Sign in Create account👤

Annexon Inc · Overview · TradingHolo

Markets › United States › NAS › ANNX

A

Annexon Inc

NAS:ANNXHealthcareCBOEFTSE:MRUTNASDAQ:NBI

$4.02+17.74%LiveIn session · ≈ AED 14.75 · Market cap $761.16M · Next earnings Mon 9 Nov

🔔 Alert▶ Test a strategy

Overview Chart Financials Valuation Forecasts Dividends Ownership Options Shorts News Profile

1D

+17.7%

1M

−18.2%

3M

−38.8%

6M

−47.9%

1Y

+12.2%

Why it's moving today

Annexon Price Target Raised to $25.00/Share From $14.00 by HC Wainwright & Co.

Dow Jones Newswires · Mon 19 Oct

✦ This week in three lines

No written digest yet for ANNX. The figures on this page are the source when one is written.

Financials

USD millions · annual5Y CAGR —

Valuation

P/E vs sector−3.1× vs −1.7×

Price / Book vs sector3.1× vs 2.0×

Price / Sales vs sector—

Price / Free cash flow vs sector−3.5× vs −1.6×

Forecasts

9 buy2 hold0 sell11 analysts

Average target$14.00 +248.7%

Analysts1

EPS surprises, last 84 beats

Dividends

Yield0.3%

Annual payout—

Payout ratio−0.9%

Next ex-date—

Years of growth—

Latest news

All ANNX news →

DOAnnexon Price Target Raised to $25.00/Share From $14.00 by HC Wainwright & Co.

Dow Jones Newswires · 13 h ago

TRHC Wainwright & Co. maintains Buy rating on Annexon, $25 price target

TradingView · 13 h ago

REAnnexon Reports Inducement Grants to New Employees

Reuters · 3 d ago

Key facts

At close · Mon 19 Oct

Market cap (USD)$761.16M

P/E−3.1×

Dividend yield0.3%

52-week range$2.54 – $7.18

Avg volume (20d)3,338,026

Shares outstanding189,579,000

Beta1.22

Short interest19.4% of float

Next earningsMon 9 Nov

Radar Score

48

Value37

Quality26

Momentum36

Income91

Peer percentile within United States Healthcare0–100 · null when more than one input is missing

About

Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The…

SectorHealthcare

IndustryNormal

ExchangeNAS

Peers

LLNYSE:LLYEli Lilly and Co · 🇺🇸 NYSE

56.9×−0.72%

JNNYSE:JNJJohnson & Johnson · 🇺🇸 NYSE

22.8×−0.56%

ABNYSE:ABBVAbbVie Inc · 🇺🇸 NYSE

118.7×−0.52%

UNNYSE:UNHUnitedHealth Group Inc · 🇺🇸 NYSE

30.3×+1.28%